Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer _ CANAL Study

NCT05725343 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT05725343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05725343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer _ CANAL Study
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 3
Overall status
Terminated
Start date
February 3, 2022
Completion date
September 21, 2022
Enrollment
350 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer